Core Viewpoint - The company has received production registration approvals from the National Medical Products Administration of China for two pharmaceutical products, enhancing its portfolio in the ophthalmic and gastrointestinal preparation sectors [1] Group 1: Product Approvals - The company has obtained a production registration approval for Levofloxacin Eye Drops (0.488% concentration, 5ml: 24.4mg), classified as a Class 4 chemical drug, which is considered to have passed the consistency evaluation [1] - Levofloxacin Eye Drops are primarily used for treating various eye conditions, including blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and for sterile chemotherapy during ophthalmic surgeries [1] - The approval enriches the company's range of ophthalmic formulations [1] Group 2: Additional Product Approvals - The company has also received approval for Compound Magnesium Sulfate Granules (10mg per bag), classified as a Class 3 chemical drug, which is also considered to have passed the consistency evaluation [1] - Compound Magnesium Sulfate Granules are mainly used for bowel cleansing prior to colonoscopy and X-ray examinations, and can also be utilized for bowel preparation before surgical procedures [1] - The company's magnesium sulfate active pharmaceutical ingredient has been approved for use in marketed formulations as of December 4, 2025 [1]
石四药集团已取得国家药监局有关左氧氟沙星滴眼液(0.488% (5ml： 24.4mg))的药品生产注册批件